Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Moreover, 24 h urine protein, serum creatinine, BUN and cystatin C increased from DKD stage II to stage IV, whereas the eGFR and urine titratable acid decreased in the same way.
|
31473080 |
2019 |
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
With regard to the rabbit model of acute renal injury in DN, compared to the PC-AKI group, the Res+PC-AKI group showed decreased levels of cystatin C and urinary neutrophil gelatinase-associated lipocalin, increased pure molecular diffusion (<i>D</i>) and the fraction of water flowing in capillaries (<i>f</i>), a decreased apparent relaxation rate (<i>R2*</i>), renal injury score and apoptosis rate, increased protein expression levels of SIRT1 and PGC-1α, and decreased levels of HIF-1α and apoptosis-associated protein.
|
31402864 |
2019 |
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This is a retrospective study included in 308 patients with type 2 diabetes and biopsy-proven DN who were followed up at least one year. eGFR was calculated using chronic kidney disease epidemiology (CKD-EPI) equations based on serum creatinine (eGFR<sub>CKD-EPI-Cr</sub>), cystatin C (eGFR<sub>CKD-EPI-CysC</sub>), and joint equations (eGFR<sub>CKD-EPI-Cr-CysC</sub>), respectively.
|
31636737 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Baseline parameters of potential subjects such as HbA1c, blood pressure, Advanced Glycation Endproduct (AGE), soluble receptor for AGE (sRAGE), Nε-Carboxymethyllysine (Nε-CML), and Cystatin C were assessed for possible correlation with diabetic nephropathy.
|
30227659 |
2018 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
The biomarker profiles associated with mortality differed significantly by CKD etiology as follows: DKD was associated with CysC (HR 1.3, 95% CI 1.0-1.6), ADMA (HR 1.3, 95% CI 1.1-1.6), and NT-proBNP (HR 1.7, 95% CI 1.4-2.1), GN was associated with FGF23 (HR 1.8, 95% CI 1.1-2.8), TnI (HR 3.6, 95% CI 1.3-9.5), and transforming growth factor-beta (HR 0.6, 95% CI 0.4-0.9) and PCK/TIN was associated with ADMA (HR 1.5, 95% CI 1.3-1.8) and IL-6 (HR 2.1, 95% CI 1.5-3.1).
|
28147348 |
2017 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curve analysis showed that Gas6 was better than cystatin C as a biomarker for early diagnosis and detection of DN, with a cutoff value of 9.435 ng/mL (86.1% sensitivity and 84.6% specificity).
|
28513288 |
2017 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
With respect to the diagnosis of DKD, the areas under the receiver operating characteristic curve (AUCs) for urinary NGAL, clusterin, and cystatin C were 0.816 (95% confidence interval [CI], 0.741-0.891), 0.775 (95% CI: 0.694-0.857), and 0.803 (95% CI: 0.722-0.884), respectively.
|
28701152 |
2017 |
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In this regard, a better diagnostic markers to serve for this purpose are creatinine clearance, fractional excretion of magnesium (FE Mg), cystatin C. Recently, renal microvascular disease and renal ischemia have been demonstrated to correlate indirectly with the development of diabetic kidney disease and its function.
|
28494191 |
2017 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
There were significant correlations between genotypes, serum Cystatin C and estimated glomerular filtration rate in patients with diabetic nephropathy.
|
26337659 |
2016 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
RGD |
Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction.
|
18946178 |
2008 |
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
It appears that the levels of serum cystatin C may predict early prognostic stages of patients with type 2 diabetic nephropathy.
|
12938144 |
2003 |